Informations

At the recently concluded ESMO Breast Cancer Congress 2026 (ESMO BC 2026), Professor Matteo Lambertini from IRCCS Ospedale Policlinico San Martino and the University of Genova served as one of the chairs of the session “Breast Cancer in Young Women (BCY) Session – Management of HR+ Breast Cancer in Young Women.” Together with fellow panelists,…

ESR1 mutation is a major mechanism of acquired resistance during first-line endocrine therapy for HR+/HER2− advanced breast cancer. At this year’s ESMO Breast Cancer Congress, Professor François Clément Bidard from Institut Curie presented screening-phase data from the SERENA-6 study (Abstract No. 419RO).

At the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Neelima Vidula from Massachusetts General Hospital presented the findings of the randomized phase II ICI-CHEST, TBCRC044 study (Abstract No. 425RO), offering important clinical insights into one of the most challenging settings in advanced breast cancer. The study investigated whether adding the PD-1 inhibitor pembrolizumab to…

At the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Sibylle Loibl from Goethe University Frankfurt presented a post hoc analysis of hyperglycemia in the INAVO120 study. The analysis explored investigator-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), and overall survival (OS) according to whether patients experienced hyperglycemia of any grade.

During the “Adjuvant Therapy for Hormone Receptor-Positive Early Breast Cancer” session at the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Sung-Bae Kim from Asan Medical Center, University of Ulsan College of Medicine, delivered an insightful presentation entitled “Adjuvant CDK4/6 Inhibitors: Could They Replace Chemotherapy for Intermediate-Risk ER+ Early Breast Cancer?” Following the session, Professor…

At the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Lajos Pusztai from Yale University presented an analysis from the neoadjuvant DESTINY-Breast11 (DB-11) study. The results demonstrated that the T-DXd-THP regimen not only increased the pathological complete response (pCR) rate to 67.3%, but also significantly shifted the overall distribution of residual cancer burden (RCB) toward…

Liquid biopsy technologies are rapidly advancing, and circulating tumor DNA (ctDNA) monitoring has demonstrated enormous potential in precision treatment for breast cancer. During the Educational Session “Adjuvant Therapy for ER-Positive Breast Cancer” at the ESMO Breast Cancer Congress (ESMO BC), Professor Heather Parsons from the Fred Hutchinson Cancer Center delivered a presentation entitled “The Role…